{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:13:41Z","timestamp":1790399621362,"version":"4.1.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s00213-014-3492-7","type":"journal-article","created":{"date-parts":[[2014,2,28]],"date-time":"2014-02-28T05:53:23Z","timestamp":1393566803000},"page":"3151-3167","source":"Crossref","is-referenced-by-count":43,"title":["In vitro and in vivo characterisation of Lu AF64280, a novel, brain penetrant phosphodiesterase (PDE) 2A inhibitor: potential relevance to cognitive deficits in schizophrenia"],"prefix":"10.1007","volume":"231","author":[{"given":"John P.","family":"Redrobe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus T.","family":"Christoffersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana P.","family":"Montezinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper F.","family":"Bastlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Carnerup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Bundgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Lerdrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Plath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,3,1]]},"reference":[{"key":"3492_CR1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0006-8993(01)03115-8","volume":"922","author":"CE Adams","year":"2001","unstructured":"Adams CE, Stitzel JA, Collins AC, Freedman R (2001) Alpha7-nicotinic receptor expression and the anatomical organization of hippocampal interneurons. Brain Res 922:180\u2013190","journal-title":"Brain Res"},{"key":"3492_CR2","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1176\/ajp.156.9.1358","volume":"156","author":"A Aleman","year":"1999","unstructured":"Aleman A, Hijman R, de Haan EH, Kahn RS (1999) Memory impairment in schizophrenia: a meta-analysis. Am J Psychiatry 156:1358\u20131366","journal-title":"Am J Psychiatry"},{"key":"3492_CR3","first-page":"83","volume":"14","author":"SA Bayer","year":"1993","unstructured":"Bayer SA, Altman J, Russo RJ, Zhang X (1993) Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14:83\u2013144","journal-title":"Neurotoxicology"},{"key":"3492_CR4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","volume":"58","author":"AT Bender","year":"2006","unstructured":"Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58:488\u2013520","journal-title":"Pharmacol Rev"},{"key":"3492_CR5","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1080\/00221309.1948.9918159","volume":"39","author":"EA Berg","year":"1948","unstructured":"Berg EA (1948) A simple objective technique for measuring flexibility in thinking. J Gen Psychol 39:15\u201322","journal-title":"J Gen Psychol"},{"key":"3492_CR6","doi-asserted-by":"crossref","first-page":"4320","DOI":"10.1523\/JNEUROSCI.20-11-04320.2000","volume":"20","author":"JM Birrell","year":"2000","unstructured":"Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320\u20134324","journal-title":"J Neurosci"},{"key":"3492_CR7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.neuropharm.2004.07.040","volume":"47","author":"FG Boess","year":"2004","unstructured":"Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47:1081\u20131092","journal-title":"Neuropharmacology"},{"key":"3492_CR8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-1119(94)90155-4","volume":"149","author":"GB Bolger","year":"1994","unstructured":"Bolger GB, Rodgers L, Riggs M (1994) Differential CNS expression of alternative mRNA isoforms of the mammalian genes encoding cAMP-specific phosphodiesterases. Gene 149:237\u2013244","journal-title":"Gene"},{"key":"3492_CR9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/(SICI)1096-9861(19971027)387:3<385::AID-CNE5>3.0.CO;2-X","volume":"387","author":"CR Breese","year":"1997","unstructured":"Breese CR, Adams C, Logel J, Drebing C, Rollins Y, Barnhart M, Sullivan B, Demasters BK, Freedman R, Leonard S (1997) Comparison of the regional expression of nicotinic acetylcholine receptor alpha7 mRNA and [125I]-alpha-bungarotoxin binding in human postmortem brain. J Comp Neurol 387:385\u2013398","journal-title":"J Comp Neurol"},{"key":"3492_CR10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.bbr.2008.02.020","volume":"190","author":"BV Broberg","year":"2008","unstructured":"Broberg BV, Dias R, Glenth\u00f8j BY, Olsen CK (2008) Evaluation of a neurodevelopmental model of schizophrenia\u2014early postnatal PCP treatment in attentional set-shifting. Behav Brain Res 190:160\u2013163","journal-title":"Behav Brain Res"},{"key":"3492_CR11","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00213-009-1540-5","volume":"206","author":"BV Broberg","year":"2009","unstructured":"Broberg BV, Glenth\u00f8j BY, Dias R, Larsen DB, Olsen CK (2009) Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia: sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology 206:631\u2013640","journal-title":"Psychopharmacology"},{"key":"3492_CR12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1006\/geno.1994.1075","volume":"19","author":"B Chini","year":"1994","unstructured":"Chini B, Raimond E, Elgoyhen AB, Moralli D, Balzaretti M, Heinemann S (1994) Molecular cloning and chromosomal localization of the human alpha 7-nicotinic receptor subunit gene (CHRNA7). Genomics 19:379\u2013381","journal-title":"Genomics"},{"key":"3492_CR13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0306-4522(01)00171-3","volume":"105","author":"B Clancy","year":"2001","unstructured":"Clancy B, Darlington RB, Finlay BL (2001) Translating developmental time across mammalian species. Neuroscience 105:7\u201317","journal-title":"Neuroscience"},{"key":"3492_CR14","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/0028-3932(93)90070-G","volume":"31","author":"L Clare","year":"1993","unstructured":"Clare L, McKenna PJ, Mortimer AM, Baddeley AD (1993) Memory in schizophrenia: what is impaired and what is preserved? Neuropsychologia 31:1225\u20131241","journal-title":"Neuropsychologia"},{"key":"3492_CR15","doi-asserted-by":"crossref","first-page":"8853","DOI":"10.1523\/JNEUROSCI.20-23-08853.2000","volume":"20","author":"RE Clark","year":"2000","unstructured":"Clark RE, Zola SM, Squire LR (2000) Impaired recognition memory in rats after damage to the hippocampus. J Neurosci 20:8853\u20138860","journal-title":"J Neurosci"},{"key":"3492_CR16","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1016\/j.bmcl.2012.07.007","volume":"22","author":"NS Cutshall","year":"2012","unstructured":"Cutshall NS, Onrust R, Rohde A, Gragerov S, Hamilton L, Harbol K, Shen HR, McKee S, Zuta C, Gragerova G, Florio V, Wheeler TN, Gage JL (2012) Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia. Bioorg Med Chem Lett 22:5595\u20135599","journal-title":"Bioorg Med Chem Lett"},{"key":"3492_CR17","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bbr.2009.09.048","volume":"207","author":"T Damgaard","year":"2010","unstructured":"Damgaard T, Larsen DB, Hansen SL, Grayson B, Neill JC, Plath N (2010) Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behav Brain Res 207:144\u2013150","journal-title":"Behav Brain Res"},{"key":"3492_CR18","first-page":"320","volume":"21","author":"SI Deutsch","year":"1998","unstructured":"Deutsch SI, Mastropaolo J, Rosse RB (1998) Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol 21:320\u2013332","journal-title":"Clin Neuropharmacol"},{"key":"3492_CR19","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1101\/lm.025015.111","volume":"20","author":"J Do","year":"2012","unstructured":"Do J, Kim JI, Bakes J, Lee K, Kaang BK (2012) Functional roles of neurotransmitters and neuromodulators in the dorsal striatum. Learn Mem 20:21\u201328","journal-title":"Learn Mem"},{"key":"3492_CR20","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1017\/S0033291700033523","volume":"25","author":"R Elliott","year":"1995","unstructured":"Elliott R, McKenna PJ, Robbins TW, Sahakian BJ (1995) Neuropsychological evidence for frontostriatal dysfunction in schizophrenia. Psychol Med 25:619\u2013626","journal-title":"Psychol Med"},{"key":"3492_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","volume":"31","author":"A Ennaceur","year":"1988","unstructured":"Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: behavioural data. Behav Brain Res 31:47\u201359","journal-title":"Behav Brain Res"},{"key":"3492_CR22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neubiorev.2010.07.001","volume":"35","author":"AK Fett","year":"2011","unstructured":"Fett AK, Viechtbauer W, Dominguez MD, Penn DL, van Os J, Krabbendam L (2011) The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis. Neurosci Biobehav Rev 35:573\u2013588","journal-title":"Neurosci Biobehav Rev"},{"key":"3492_CR23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0006-3223(94)00252-X","volume":"38","author":"R Freedman","year":"1995","unstructured":"Freedman R, Hall M, Adler LE, Leonard S (1995) Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38:22\u201333","journal-title":"Biol Psychiatry"},{"key":"3492_CR24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.94.2.587","volume":"94","author":"R Freedman","year":"1997","unstructured":"Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A, Polymeropoulos M, Holik J, Hopkins J, Hoff M, Rosenthal J, Waldo MC, Reimherr F, Wender P, Yaw J, Young DA, Breese CR, Adams C, Patterson D, Adler LE, Kruglyak L, Leonard S, Byerley W (1997) Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 94:587\u2013592","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3492_CR25","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/(SICI)1096-8628(200021)97:1<58::AID-AJMG8>3.0.CO;2-Y","volume":"97","author":"R Freedman","year":"2000","unstructured":"Freedman R, Adams CE, Adler LE, Bickford PC, Gault J, Harris JG, Nagamoto HT, Olincy A, Ross RG, Stevens KE, Waldo M, Leonard S (2000) Inhibitory neurophysiological deficit as a phenotype for genetic investigation of schizophrenia. Am J Med Genet 97:58\u201364","journal-title":"Am J Med Genet"},{"key":"3492_CR26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00213-008-1132-9","volume":"202","author":"P Goetghebeur","year":"2009","unstructured":"Goetghebeur P, Dias R (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat: a back translational study. Psychopharmacology 202:287\u2013293","journal-title":"Psychopharmacology"},{"key":"3492_CR27","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00213-010-1990-9","volume":"212","author":"PJ Goetghebeur","year":"2010","unstructured":"Goetghebeur PJ, Lerdrup L, Sylvest A, Dias R (2010) Erythropoietin reverses the attentional set-shifting impairment in a rodent schizophrenia disease-like model. Psychopharmacology 212:635\u2013642","journal-title":"Psychopharmacology"},{"key":"3492_CR28","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-1781(94)90103-1","volume":"53","author":"MF Green","year":"1994","unstructured":"Green MF, Bracha HS, Satz P, Christenson CD (1994) Preliminary evidence for an association between minor physical anomalies and second trimester neurodevelopment in schizophrenia. Psychiatry Res 53:119\u2013127","journal-title":"Psychiatry Res"},{"key":"3492_CR29","doi-asserted-by":"crossref","unstructured":"Green MF, Kern RS, Heaton RK (2004) Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res 72:41\u201351","DOI":"10.1016\/j.schres.2004.09.009"},{"key":"3492_CR30","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","volume":"158","author":"PD Harvey","year":"2001","unstructured":"Harvey PD, Keefe RSE (2001) Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158:176\u2013184","journal-title":"Am J Psychiatry"},{"key":"3492_CR31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0165-1781(96)02940-X","volume":"65","author":"MW Haut","year":"1996","unstructured":"Haut MW, Cahill J, Cutlip WD, Stevenson JM, Makela EH, Bloomfield SM (1996) On the nature of Wisconsin card sorting test performance in schizophrenia. Psychiatry Res 65:15\u201322","journal-title":"Psychiatry Res"},{"key":"3492_CR32","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0006-3223(00)00919-7","volume":"48","author":"S Heckers","year":"2000","unstructured":"Heckers S, Curran T, Goff D, Rauch SL, Fischman AJ, Alpert NM, Schacter DL (2000) Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia. Biol Psychiatry 48:651\u2013657","journal-title":"Biol Psychiatry"},{"key":"3492_CR33","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1021\/jm2001508","volume":"54","author":"CJ Helal","year":"2011","unstructured":"Helal CJ, Kang Z, Hou X, Pandit J, Chappie TA, Humphrey JM, Marr ES, Fennell KF, Chenard LK, Fox C, Schmidt CJ, Williams RD, Chapin DS, Siuciak J, Lebel L, Menniti F, Cianfrogna J, Fonseca KR, Nelson FR, O\u2019Connor R, MacDougall M, McDowell L, Liras S (2011) Use of structure-based design to discover a potent, selective, in vivo active phosphodiesterase 10A inhibitor lead series for the treatment of schizophrenia. J Med Chem 54:4536\u20134547","journal-title":"J Med Chem"},{"key":"3492_CR34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2007.06.052","volume":"573","author":"P Hertel","year":"2007","unstructured":"Hertel P, Didriksen M, Pouzet B, Brennum LT, S\u00f8by KK, Larsen AK, Christoffersen CT, Ramirez T, Marcus MM, Svensson TH, Di Matteo V, Esposito E, Bang-Andersen B, Arnt J (2007) Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: characterisation of its in vitro profile and pre-clinical antipsychotic potential. Eur J Pharmacol 573:148\u2013160","journal-title":"Eur J Pharmacol"},{"key":"3492_CR35","doi-asserted-by":"crossref","first-page":"14224","DOI":"10.1073\/pnas.1207461109","volume":"109","author":"Y Hu","year":"2012","unstructured":"Hu Y, Wu DL, Luo CX, Zhu LJ, Zhang J, Wu HY, Zhu DY (2012) Hippocampal nitric oxide contributes to sex difference in affective behaviors. Proc Natl Acad Sci U S A 109:14224\u201314229","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3492_CR36","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1017\/S0033291797006041","volume":"28","author":"SB Hutton","year":"1998","unstructured":"Hutton SB, Puri BK, Duncan LJ, Robbins TW, Barnes TRE, Joyce EM (1998) Executive function in first-episode schizophrenia. Psychol Med 28:463\u2013473","journal-title":"Psychol Med"},{"key":"3492_CR37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00213-009-1702-5","volume":"208","author":"N Idris","year":"2010","unstructured":"Idris N, Neill J, Grayson B, Bang-Andersen B, Witten LM, Brennum LT, Arnt J (2010) Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT(2A) receptor mechanisms. Psychopharmacology 208:23\u201336","journal-title":"Psychopharmacology"},{"key":"3492_CR38","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201\u2013225","journal-title":"Neuropsychopharmacology"},{"key":"3492_CR39","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/bdd.325","volume":"23","author":"JC Kalvass","year":"2002","unstructured":"Kalvass JC, Maurer TS (2002) Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharm Drug Dispos 23:327\u2013338","journal-title":"Biopharm Drug Dispos"},{"key":"3492_CR40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"RS Keefe","year":"2007","unstructured":"Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA, CATIE Investigators, Neurocognitive Working Group (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633\u2013647","journal-title":"Arch Gen Psychiatry"},{"key":"3492_CR41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cellsig.2013.10.007","volume":"26","author":"MP Kelly","year":"2014","unstructured":"Kelly MP, Adamowicz W, Bove S, Hartman AJ, Mariga A, Pathak G, Reinhart V, Romegialli A, Kleiman RJ (2014) Select 3\u2032,5\u2032-cyclic nucleotide phosphodiesterases exhibit altered expression in the aged rodent brain. Cell Signal 26:383\u2013397","journal-title":"Cell Signal"},{"key":"3492_CR42","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/978-3-540-68964-5_5","volume":"191","author":"T Kleppisch","year":"2009","unstructured":"Kleppisch T (2009) Phosphodiesterases in the central nervous system. Handb Exp Pharmacol 191:71\u201392","journal-title":"Handb Exp Pharmacol"},{"key":"3492_CR43","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/978-3-540-68964-5_24","volume":"191","author":"T Kleppisch","year":"2009","unstructured":"Kleppisch T, Feil R (2009) cGMP signalling in the mammalian brain: role in synaptic plasticity and behaviour. Handb Exp Pharmacol 191:549\u2013579","journal-title":"Handb Exp Pharmacol"},{"key":"3492_CR44","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.biopsych.2009.05.016","volume":"66","author":"VC Leeson","year":"2009","unstructured":"Leeson VC, Robbins TW, Matheson E, Hutton SB, Ron MA, Barnes TR, Joyce EM (2009) Discrimination learning, reversal, and set-shifting in first-episode schizophrenia: stability over six years and specific associations with medication type and disorganization syndrome. Biol Psychiatry 66:586\u2013593","journal-title":"Biol Psychiatry"},{"key":"3492_CR45","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0031-6997(24)01457-1","volume":"52","author":"KA Lucas","year":"2000","unstructured":"Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375\u2013414","journal-title":"Pharmacol Rev"},{"key":"3492_CR46","doi-asserted-by":"crossref","first-page":"12375","DOI":"10.1073\/pnas.220398097","volume":"97","author":"JR Manns","year":"2000","unstructured":"Manns JR, Stark CEL, Squire LR (2000) The visual paired-comparison task as a measure of declarative memory. Proc Natl Acad Sci U S A 97:12375\u201312379","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3492_CR47","doi-asserted-by":"crossref","unstructured":"Masood A, Huang Y, Hajjhussein H, Xiao L, Li H, Wang W, Hamza A, Zhan CG, O'Donnell JM (2009) Anxiolytic effects of phosphodiesterase-2 inhibitors associated with increased cGMP signaling. J Pharmacol Exp Ther 331:690\u2013699","DOI":"10.1124\/jpet.109.156729"},{"key":"3492_CR48","doi-asserted-by":"crossref","unstructured":"McLean SL, Beck JP, Woolley ML, Neill JC (2008) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152\u2013158","DOI":"10.1016\/j.bbr.2007.12.029"},{"key":"3492_CR49","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.euroneuro.2010.06.003","volume":"21","author":"SL McLean","year":"2010","unstructured":"McLean SL, Grayson B, Idris NF, Lesage AS, Pemberton DJ, Mackie C, Neill JC (2010) Activation of alpha7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol 21:333\u2013343","journal-title":"Eur Neuropsychopharmacol"},{"key":"3492_CR50","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0306-4522(95)00249-I","volume":"69","author":"CL Miller","year":"1995","unstructured":"Miller CL, Freedman R (1995) The activity of hippocampal interneurons and pyramidal cells during the response of the hippocampus to repeated auditory stimuli. Neuroscience 69:371\u2013381","journal-title":"Neuroscience"},{"key":"3492_CR51","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1093\/schbul\/sbn078","volume":"34","author":"GK Murray","year":"2008","unstructured":"Murray GK, Cheng F, Clark L, Barnett JH, Blackwell AD, Fletcher PC, Robbins TW, Bullmore ET, Jones PB (2008) Reinforcement and reversal learning in first-episode psychosis. Schizophr Bull 34:848\u2013855","journal-title":"Schizophr Bull"},{"key":"3492_CR52","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.pharmthera.2010.07.004","volume":"128","author":"JC Neill","year":"2010","unstructured":"Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther 128:419\u2013432","journal-title":"Pharmacol Ther"},{"key":"3492_CR53","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/schbul\/sbq004","volume":"36","author":"CM O\u2019Tuathaigh","year":"2010","unstructured":"O\u2019Tuathaigh CM, Waddington JL (2010) Mutant mouse models: phenotypic relationships to domains of psychopathology and pathobiology in schizophrenia. Schizophr Bull 36:243\u2013245","journal-title":"Schizophr Bull"},{"key":"3492_CR54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/0888-7543(95)80228-E","volume":"26","author":"A Orr-Urtreger","year":"1995","unstructured":"Orr-Urtreger A, Seldin MF, Baldini A, Beaudet AL (1995) Cloning and mapping of the mouse alpha 7-neuronal nicotinic acetylcholine receptor. Genomics 26:399\u2013402","journal-title":"Genomics"},{"key":"3492_CR55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0920-9964(98)00156-X","volume":"37","author":"C Pantelis","year":"1999","unstructured":"Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251\u2013270","journal-title":"Schizophr Res"},{"key":"3492_CR56","unstructured":"Paxinos G and Franklin K (2001) Paxinos and Franklin's the mouse brain in stereotaxic coordinates. Second edition, Academic Press, San Diego"},{"key":"3492_CR57","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jneumeth.2009.09.014","volume":"185","author":"CS Pedersen","year":"2009","unstructured":"Pedersen CS, Goetghebeur P, Dias R (2009) Chronic infusion of PCP via osmotic mini-pumps: a new rodent model of cognitive deficit in schizophrenia characterized by impaired attentional set-shifting (ID\/ED) performance. J Neurosci Methods 185:66\u201369","journal-title":"J Neurosci Methods"},{"key":"3492_CR58","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1016\/j.bmcl.2013.03.082","volume":"23","author":"MS Plummer","year":"2013","unstructured":"Plummer MS, Cornicelli J, Roark H, Skalitzky DJ, Stankovic CJ, Bove S, Pandit J, Goodman A, Hicks J, Shahripour A, Beidler D, Lu XK, Sanchez B, Whitehead C, Sarver R, Braden T, Gowan R, Shen XQ, Welch K, Ogden A, Sadagopan N, Baum H, Miller H, Banotai C, Spessard C, Lightle S (2013) Discovery of potent selective bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model. Part II: Optimization studies and demonstration of in vivo efficacy. Bioorg Med Chem Lett 23:3443\u20133447","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"3492_CR59","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fpsyt.2010.00146","volume":"1","author":"JP Redrobe","year":"2010","unstructured":"Redrobe JP, Bull S, Plath N (2010) Translational aspects of the novel object recognition task in rats abstinent following sub-chronic treatment with phencyclidine (PCP): effects of modafinil and relevance to cognitive deficits in schizophrenia. Front Psychiatry 1:146","journal-title":"Front. Psychiatry"},{"key":"3492_CR60","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00213-011-2593-9","volume":"221","author":"JP Redrobe","year":"2012","unstructured":"Redrobe JP, Elster L, Frederiksen K, Bundgaard C, de Jong IE, Smith GP, Bruun AT, Larsen PH, Didriksen M (2012) Negative modulation of GABAA \u03b15 receptors by RO4938581 attenuates discrete sub-chronic and early postnatal phencyclidine (PCP)-induced cognitive deficits in rats. Psychopharmacology 221:451\u2013468","journal-title":"Psychopharmacology"},{"key":"3492_CR61","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00213-008-1273-x","volume":"202","author":"OA Reneerkens","year":"2009","unstructured":"Reneerkens OA, Rutten K, Steinbusch HW, Blokland A, Prickaerts J (2009) Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology 202:419\u2013443","journal-title":"Psychopharmacology"},{"key":"3492_CR62","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.bbr.2012.08.019","volume":"236","author":"OA Reneerkens","year":"2013","unstructured":"Reneerkens OA, Rutten K, Bollen E, Hage T, Blokland A, Steinbusch HW, Prickaerts J (2013) Inhibition of phoshodiesterase type 2 or type 10 reverses object memory deficits induced by scopolamine or MK-801. Behav Brain Res 236:16\u201322","journal-title":"Behav Brain Res"},{"key":"3492_CR63","doi-asserted-by":"crossref","first-page":"18683","DOI":"10.1016\/S0021-9258(19)37015-2","volume":"267","author":"DR Repaske","year":"1992","unstructured":"Repaske DR, Swinnen JV, Jin SL, Van Wyk JJ, Conti M (1992) A polymerase chain reaction strategy to identify and clone cyclic nucleotide phosphodiesterase cDNAs. Molecular cloning of the cDNA encoding the 63-kDa calmodulin-dependent phosphodiesterase. J Biol Chem 267:18683\u201318688","journal-title":"J Biol Chem"},{"key":"3492_CR64","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","volume":"25","author":"E Reyes-Irisarri","year":"2007","unstructured":"Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, de Vente J (2007) Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer\u2019s disease human brains. Eur J Neurosci 25:3332\u20133338","journal-title":"Eur J Neurosci"},{"key":"3492_CR65","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/j.1460-9568.2005.03937.x","volume":"21","author":"JS Rodefer","year":"2005","unstructured":"Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21:1070\u20131076","journal-title":"Eur J Neurosci"},{"key":"3492_CR66","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1038\/sj.npp.1301654","volume":"33","author":"JS Rodefer","year":"2008","unstructured":"Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT6 receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657\u20132666","journal-title":"Neuropsychopharmacology"},{"key":"3492_CR67","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.neuropharm.2011.08.008","volume":"62","author":"JS Rodefer","year":"2012","unstructured":"Rodefer JS, Saland SK, Eckrich SJ (2012) Selective phosphodiesterase inhibitors improve performance on the ED\/ID cognitive task in rats. Neuropharmacology 62:1182\u20131190","journal-title":"Neuropharmacology"},{"key":"3492_CR68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-1119(97)00046-2","volume":"191","author":"GJ Rosman","year":"1997","unstructured":"Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K, Loughney K (1997) Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3\u2032,5\u2032-cyclic nucleotide phosphodiesterase. Gene 191:89\u201395","journal-title":"Gene"},{"key":"3492_CR69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1177\/002215549904700707","volume":"47","author":"K Sadhu","year":"1999","unstructured":"Sadhu K, Hensley K, Florio VA, Wolda SL (1999) Differential expression of the cyclic GMP-stimulated phosphodiesterase PDE2A in human venous and capillary endothelial cells. J Histochem Cytochem 47:895\u2013906","journal-title":"J Histochem Cytochem"},{"key":"3492_CR70","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/111.3.695","volume":"111","author":"BJ Sahakian","year":"1988","unstructured":"Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, Robbins TW (1988) A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson\u2019s disease. Brain 111:695\u2013718","journal-title":"Brain"},{"key":"3492_CR71","doi-asserted-by":"crossref","first-page":"222","DOI":"10.2174\/156802610790411009","volume":"10","author":"CJ Schmidt","year":"2010","unstructured":"Schmidt CJ (2010) Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Top Med Chem 10:222\u2013230","journal-title":"Curr Top Med Chem"},{"key":"3492_CR72","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(03)02754-9","volume":"985","author":"TF Seeger","year":"2003","unstructured":"Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985:113\u2013126","journal-title":"Brain Res"},{"key":"3492_CR73","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0193-953X(02)00084-9","volume":"26","author":"T Sharma","year":"2003","unstructured":"Sharma T, Antonova L (2003) Cognitive function in schizophrenia: deficits, functional consequences, and future treatment. Psychiatr Clin North Am 26:25\u201340","journal-title":"Psychiatr. Clin. North. Am."},{"key":"3492_CR74","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00213-009-1568-6","volume":"206","author":"P Singer","year":"2009","unstructured":"Singer P, Feldon J, Yee BK (2009) Are DBA\/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL\/6 mice. Psychopharmacology 206:677\u2013698","journal-title":"Psychopharmacology"},{"key":"3492_CR75","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.neuropharm.2012.06.013","volume":"64","author":"SM Smith","year":"2013","unstructured":"Smith SM, Uslaner JM, Cox CD, Huszar SL, Cannon CE, Vardigan JD, Eddins D, Toolan DM, Kandebo M, Yao L, Raheem IT, Schreier JD, Breslin MJ, Coleman PJ, Renger JJ (2013) The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey. Neuropharmacology 64:215\u2013223","journal-title":"Neuropharmacology"},{"key":"3492_CR76","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1124\/jpet.109.156349","volume":"332","author":"S Snigdha","year":"2010","unstructured":"Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY (2010) Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimivanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. J Pharmacol Exp Ther 332:622\u2013631","journal-title":"J Pharmacol Exp Ther"},{"key":"3492_CR77","doi-asserted-by":"crossref","first-page":"17655","DOI":"10.1016\/S0021-9258(19)47421-8","volume":"266","author":"WK Sonnenburg","year":"1991","unstructured":"Sonnenburg WK, Mullaney PJ, Beavo JA (1991) Molecular cloning of a cyclic GMP-stimulated cyclic nucleotide phosphodiesterase cDNA. Identification and distribution of isozyme variants. J Biol Chem 266:17655\u201317661","journal-title":"J. Biol. Chem."},{"key":"3492_CR78","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1124\/jpet.108.146944","volume":"328","author":"F Sotty","year":"2009","unstructured":"Sotty F, Damgaard T, Montezinho LP, M\u00f8rk A, Olsen CK, Bundgaard C, Husum H (2009a) Antipsychotic-like effect of retigabine [N-(2-amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission. J Pharmacol Exp Ther 328:951\u2013962","journal-title":"J Pharmacol Exp Ther"},{"key":"3492_CR79","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2009.06004.x","volume":"109","author":"F Sotty","year":"2009","unstructured":"Sotty F, Montezinho LP, Steiniger-Brach B, Nielsen J (2009b) Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons. J Neurochem 109:766\u2013775","journal-title":"J Neurochem"},{"key":"3492_CR80","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1369\/jhc.2009.953471","volume":"57","author":"DT Stephenson","year":"2009","unstructured":"Stephenson DT, Coskran TM, Wilhelms MB, Adamowicz WO, O\u2019Donnell MM, Muravnick KB, Menniti FS, Kleiman RJ, Morton D (2009) Immunohistochemical localization of phosphodiesterase 2A in multiple mammalian species. J Histochem Cytochem 57:933\u2013949","journal-title":"J Histochem Cytochem"},{"key":"3492_CR81","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.neuroscience.2012.09.011","volume":"226","author":"DT Stephenson","year":"2012","unstructured":"Stephenson DT, Coskran TM, Kelly MP, Kleiman RJ, Morton D, O\u2019Neill SM, Schmidt CJ, Weinberg RJ, Menniti FS (2012) The distribution of phosphodiesterase 2A in the rat brain. Neuroscience 226:145\u2013155","journal-title":"Neuroscience"},{"key":"3492_CR82","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S0091-3057(96)00466-2","volume":"57","author":"KE Stevens","year":"1997","unstructured":"Stevens KE, Wear KD (1997) Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav 57:869\u2013874","journal-title":"Pharmacol Biochem Behav"},{"key":"3492_CR83","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/0893-133X(95)00178-G","volume":"15","author":"KE Stevens","year":"1996","unstructured":"Stevens KE, Freedman R, Collins AC, Hall M, Leonard S, Marks MJ, Rose GM (1996) Genetic correlation of inhibitory gating of hippocampal auditory evoked response and alpha-bungarotoxin-binding nicotinic cholinergic receptors in inbred mouse strains. Neuropsychopharmacology 15:152\u2013162","journal-title":"Neuropsychopharmacology"},{"key":"3492_CR84","doi-asserted-by":"crossref","first-page":"3642","DOI":"10.1021\/jm0407613","volume":"47","author":"LJ Street","year":"2004","unstructured":"Street LJ, Sternfeld F, Jelley RA, Reeve AJ, Carling RW, Moore KW, McKernan RM, Sohal B, Cook S, Dawson GR, Bromidge FA, Wafford KA, Seabrook GR, Thompson SA, Marshall G, Pillai GV, Castro JL, Atack JR, MacLeod AM (2004) Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site. J Med Chem 47:3642\u20133657","journal-title":"J Med Chem"},{"key":"3492_CR85","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1001\/archpsyc.59.2.146","volume":"59","author":"C Tek","year":"2002","unstructured":"Tek C, Gold J, Blaxton T, Wilk C, McMahon RP, Buchanan RW (2002) Visual perceptual and working memory impairments in schizophrenia. Arch Gen Psychiatry 59:146\u2013153","journal-title":"Arch Gen Psychiatry"},{"key":"3492_CR86","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/sj.npp.1300457","volume":"29","author":"DC Turner","year":"2004","unstructured":"Turner DC, Clark L, Pomarol-Clotet E, McKenna P, Robbins TW, Sahakian BJ (2004) Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 29:1363\u20131373","journal-title":"Neuropsychopharmacology"},{"key":"3492_CR87","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/adsc.200404005","volume":"346","author":"S Urgaonkar","year":"2004","unstructured":"Urgaonkar S, Verkade JG (2004) Palladium\/proazaphosphatrane-catalyzed amination of aryl halides possessing a phenol, alcohol, acetanilide, amide or an enolizable ketone functional group: efficacy of lithium bis(trimethylsilyl)amide as the base. Adv Synth Catal 346:611\u2013616","journal-title":"Adv Synth Catal"},{"key":"3492_CR88","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ejphar.2008.10.027","volume":"600","author":"EL Donkelaar van","year":"2008","unstructured":"van Donkelaar EL, Rutten K, Blokland A, Akkerman S, Steinbusch HW, Prickaerts J (2008) Phosphodiesterase 2 and 5 inhibition attenuates the object memory deficit induced by acute tryptophan depletion. Eur J Pharmacol 600:98\u2013104","journal-title":"Eur J Pharmacol"},{"key":"3492_CR89","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/cne.10955","volume":"467","author":"WC Staveren van","year":"2003","unstructured":"van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J (2003) mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467:566\u2013580","journal-title":"J Comp Neurol"},{"key":"3492_CR90","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.0953-816X.2004.03327.x","volume":"19","author":"WC Staveren van","year":"2004","unstructured":"van Staveren WC, Steinbusch HW, Markerink-van Ittersum M, Behrends S, de Vente J (2004) Species differences in the localization of cGMP-producing and NO-responsive elements in the mouse and rat hippocampus using cGMP immunocytochemistry. Eur J Neurosci 19:2155\u20132168","journal-title":"Eur J Neurosci"},{"key":"3492_CR91","doi-asserted-by":"crossref","first-page":"358","DOI":"10.2174\/138161210790170085","volume":"16","author":"ML Wadenberg","year":"2010","unstructured":"Wadenberg ML (2010) Conditioned avoidance response in the development of new antipsychotics. Curr Pharm Des 16:358\u2013370","journal-title":"Curr Pharm Des"},{"key":"3492_CR92","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/0024-3205(87)90695-3","volume":"41","author":"BHC Westerink","year":"1987","unstructured":"Westerink BHC, Damsma G, Rollema H, de Vries JB, Horn AS (1987) Scope and limitations of in vivo brain dialysis: a comparison of its application to various neurotransmitter systems. Life Sci 41:1763\u20131776","journal-title":"Life Sci"},{"key":"3492_CR93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3940(82)90085-4","volume":"34","author":"JF Willott","year":"1982","unstructured":"Willott JF, Demuth RM, Lu SM, van Bergem P (1982) Abnormal tonotopic organization in the ventral cochlear nucleus of the hearing-impaired DBA\/2 mouse. Neurosci Lett 34:13\u201317","journal-title":"Neurosci Lett"},{"key":"3492_CR94","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3371\/CSRP.4.2.4","volume":"4","author":"C Wilson","year":"2010","unstructured":"Wilson C, Terry AV Jr (2010) Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and development. Clin Schizophr Relat Psychoses 4:124\u2013137","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"3492_CR95","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/978-3-642-17969-3_19","volume":"204","author":"Y Xu","year":"2011","unstructured":"Xu Y, Zhang HT, O\u2019Donnell JM (2011) Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 204:447\u2013485","journal-title":"Handb Exp Pharmacol"},{"key":"3492_CR96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.pharmthera.2009.02.004","volume":"122","author":"JW Young","year":"2009","unstructured":"Young JW, Powell SB, Risbrough V, Marston HM, Geyer MA (2009) Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol Ther 122:150\u2013202","journal-title":"Pharmacol Ther"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3492-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-014-3492-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-014-3492-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T23:25:03Z","timestamp":1746141903000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-014-3492-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,1]]},"references-count":96,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["3492"],"URL":"https:\/\/doi.org\/10.1007\/s00213-014-3492-7","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,1]]}}}